Patents Assigned to Sankyo Company Limited
-
Publication number: 20240082413Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-Lb-Lc- wherein the antibody is connected to the terminal of L1, and the antitumor compound is connected to the terminal of Lc with the nitrogen atom of the amino group at position 1 as a connecting position.Type: ApplicationFiled: March 3, 2023Publication date: March 14, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Takeshi MASUDA, Hiroyuki NAITO, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Hideki MIYAZAKI, Yuji KASUYA, Koji MORITA, Yuki ABE, Yusuke OGITANI
-
Patent number: 11926655Abstract: The present invention provides a novel peptide that has an amino acid sequence represented by SEQ ID NO: 18, and binds to an active protease but does not bind to a pro-protease.Type: GrantFiled: July 17, 2018Date of Patent: March 12, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Hidenori Yano, Daisuke Nishimiya, Ryuji Hashimoto, Yoichi Niitsu
-
Patent number: 11884678Abstract: The present disclosure provides a method for efficiently producing and providing compounds having a spirooxindole skeleton, for example compounds having a spirooxindole skeleton and having antitumor activity that inhibit the interaction between Mdm2 protein and p53 protein, or intermediates thereof, using an asymmetric catalyst. Compounds having optically active tricyclic dispiroindole skeletons are obtained through catalytic asymmetric 1,3-dipolar cycloaddition reaction using ketimine as a reaction substrate and using a chiral ligand and a Lewis acid.Type: GrantFiled: October 27, 2020Date of Patent: January 30, 2024Assignee: Daiichi Sankyo Company, LimitedInventors: Motoshi Yamauchi, Keiji Nakayama
-
Publication number: 20240026030Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La—(CH2)n2—C(?O)—wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2—C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.Type: ApplicationFiled: September 12, 2023Publication date: January 25, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki NAITO, Yusuke OGITANI, Takeshi MASUDA, Takashi NAKADA, Masao YOSHIDA, Shinji ASHIDA, Koji MORITA, Hideki MIYAZAKI, Yuji KASUYA, Ichiro HAYAKAWA, Yuki ABE
-
Patent number: 11866472Abstract: To provide a novel pharmaceutical use of a peptide. A pharmaceutical composition for the treatment or prevention of retinitis pigmentosa, comprising a peptide which comprises the amino acid sequence shown in SEQ ID NO: 30 and inhibits the protease activity.Type: GrantFiled: June 21, 2019Date of Patent: January 9, 2024Assignee: Daiichi Sankyo Company, LimitedInventor: Tatsuya Inoue
-
Publication number: 20240002425Abstract: The present invention provides a novel compound or a pharmaceutically acceptable salt thereof which has a TLR4 activating effect and can be used as an immunostimulant or an adjuvant in vaccines or allergen immunotherapy. The present invention provides a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof. In this context, X, Y, Z and n in the formula (I) are each as defined herein.Type: ApplicationFiled: November 10, 2021Publication date: January 4, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Kobayashi, Tatsuya Oka, Yoshiko Fukuyama
-
Publication number: 20240000954Abstract: A complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention. Furthermore, a complex of ?(1?3) glucan and a nucleic acid, and having a controlled particle size is provided by the present invention.Type: ApplicationFiled: November 11, 2021Publication date: January 4, 2024Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Ken ISHII, Takato KUSAKABE, Yuji KASUYA, Nao JONAI, Fumihiko TAKESHITA, Isshin TANAKA, Emi KUROSAWA, Kyosuke SUZUKI, Tetsufumi KOGA, Yoshihiro MIYAJI
-
Patent number: 11859006Abstract: This application relates to a pharmaceutical composition for use in a method for treating and/or preventing a patient having ectopic ossification and/or brain tumor, wherein the patient has an active mutation in ALK2 protein which is responsible for ectopic ossification or brain tumor; an amino acid residue at position 330 of ALK2 is proline; and an active ingredient of this composition is an anti-ALK2 antibody or an antigen-binding fragment thereof comprising a property of binding to ALK2, a property of cross-linking ALK2, and a property of inhibiting BMP signal transduction.Type: GrantFiled: March 4, 2019Date of Patent: January 2, 2024Assignees: Saitama Medical University, Daiichi Sankyo Company, LimitedInventors: Takenobu Katagiri, Sho Tsukamoto, Keigo Kumagai, Shinnosuke Tsuji
-
Publication number: 20230414778Abstract: A pharmaceutical composition and a method of treatment having excellent antitumor effect and safety are provided. A pharmaceutical composition and a method of treatment wherein an antibody-drug conjugate, in which a drug-linker and an antibody are bound by a thioether bond represented by the following formula (A represents the binding position with an antibody), and a SIRP?-CD47 interaction inhibitor, such as an anti-SIRP? antibody, are administrated in combination. Alternatively, a pharmaceutical composition and a method of treatment wherein said antibody-drug conjugate and SIRP?-CD47 interaction inhibitor, such as an anti-SIRP? antibody, are administrated in combination and are used for the treatment of a disease improved by an action of activating antitumor immunity.Type: ApplicationFiled: November 10, 2021Publication date: December 28, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Mayumi SUE, Takuya TSUBAKI, Yoko ISHIMOTO
-
Patent number: 11845786Abstract: A novel peptide which comprises an amino acid sequence represented by SEQ ID NO: 23, and specifically inhibits the protease activity of a target molecule.Type: GrantFiled: November 22, 2021Date of Patent: December 19, 2023Assignee: Daiichi Sankyo Company, LimitedInventors: Daisuke Nishimiya, Masakazu Tamura
-
Publication number: 20230398230Abstract: A therapeutic agent for mesothelioma comprising, as an active component, an anti-B7-H3 antibody-drug conjugate in which a drug-linker represented by the following formula, wherein A represents a connecting position to an anti-B7-H3 antibody; is conjugated to the anti-B7-H3 antibody via a thioether bond, and/or a method of treatment for mesothelioma, comprising administering the anti-B7-H3 antibody-drug conjugate to a subject in need of treatment for mesothelioma.Type: ApplicationFiled: November 11, 2021Publication date: December 14, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventor: Michiko YAMATO
-
Patent number: 11834427Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: R1: e.g., a C1-C6 alkyl group; R2: a C1-C6 alkyl group; A: e.g., an oxygen atom; and R3: e.g., a C1-C6 alkyl group.Type: GrantFiled: October 13, 2022Date of Patent: December 5, 2023Assignee: Daiichi Sankyo Company, LimitedInventors: Keiji Saito, Katsuyoshi Nakajima, Toru Taniguchi, Osamu Iwamoto, Satoshi Shibuya, Yasuyuki Ogawa, Kazumasa Aoki, Nobuya Kurikawa, Shinji Tanaka, Momoko Ogitani, Eriko Kioi, Kaori Ito, Natsumi Nishihama, Tsuyoshi Mikkaichi, Wataru Saitoh
-
Publication number: 20230372527Abstract: A pharmaceutical product for administration of an anti-HER2 antibody-drug conjugate in combination with a PARP1 selective inhibitor is provided. The anti-HER2 antibody drug conjugate is an antibody-drug conjugate in which a drug-linker represented by the following formula (wherein A represents the connecting position to an antibody) is conjugated to an anti-HER2 antibody via a thioether bond. Also provided is a therapeutic use and method wherein the antibody-drug conjugate and the PARP1 selective inhibitor are administered in combination to a subject: Formula (I).Type: ApplicationFiled: October 8, 2021Publication date: November 23, 2023Applicants: AstraZeneca UK Limited, Daiichi Sankyo Company, LimitedInventors: Jerome Thomas METTETAL, II, Azadeh Cheraghchi Bashi ASTANEH, Elisabetta LEO, Yann WALLEZ
-
Patent number: 11806339Abstract: The present invention provides a medicament comprising a compound represented by general formula (1) which has Axl inhibitory activity, and an EGFR tyrosine kinase inhibitor in combination, and a method for treating cancer using this combination. The present invention provides an excellent medicament and method for treating cancer which is highly effective for inhibiting resistance to an EGFR tyrosine kinase inhibitor in cancer treatment, and causes less adverse reactions such as weight loss.Type: GrantFiled: May 2, 2022Date of Patent: November 7, 2023Assignee: Daiichi Sankyo Company, LimitedInventor: Takeshi Jimbo
-
Publication number: 20230348616Abstract: An antibody that can be used as an anti-tumor agent and an anti-tumor agent comprises a molecule containing such an antibody. Such an antibody or a binding fragment thereof comprises: a heavy chain CDRH1 consisting of SEQ ID NO: 54, a heavy chain CDRH2 consisting of SEQ ID NO: 55, a heavy chain CDRH3 consisting of SEQ ID NO: 56, a light chain CDRL1 consisting of SEQ ID NO: 57 or a light chain CDRL1 consisting of an amino acid sequence derived from SEQ ID NO: 57 in which amino acid 7 is W and/or amino acid 8 is K, a light chain CDRL2 consisting of SEQ ID NO: 58, and a light chain CDRL3 consisting of SEQ ID NO: 59 or a light chain CDRL3 consisting of an amino acid sequence derived from SEQ ID NO: 59 in which amino acid 2 is A or S.Type: ApplicationFiled: March 29, 2021Publication date: November 2, 2023Applicants: MIE UNIVERSITY, DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroshi SHIKU, Yasushi AKAHORI, Kento TANAKA, Ayaka YATSU, Junya ICHIKAWA, Toshiaki OHTSUKA, Shiho KOZUMA, Ryuji HASHIMOTO, Makiko NAKAYAMA, Naoya SHINOZAKI, Kensuke NAKAMURA, Ichiro WATANABE, Shinji FURUZONO
-
Publication number: 20230348522Abstract: The present invention provides a crystalline 2,4-bridged common intermediate useful for producing a plurality of ENA monomers, a method for stereoselectively producing the intermediate, and a method for efficiently producing ENA monomers using the intermediate.Type: ApplicationFiled: October 16, 2020Publication date: November 2, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Makoto Michida, Kazutoshi Ukai, Yuzo Abe, Moe Matsumoto, Makoto Yamaoka, Kei Kurahashi
-
Publication number: 20230340118Abstract: An object of the present invention is to provide a novel anti-CD147 antibody exhibiting potent antitumor efficacy and having excellent safety. Another object of the present invention is to provide a pharmaceutical product comprising such an antibody. Another object of the present invention is to provide a method for treating tumors using the antibody or the pharmaceutical product, for example. The present invention provides a CD147-specific antibody that activates CD147 and exhibits high antitumor efficacy. The present invention provides the anti-CD147 antibody that exhibits high antitumor efficacy independent of effector functions. The present invention provides a pharmaceutical composition comprising such an anti-CD147 antibody. The present invention provides a method for treating tumors using such an anti-CD147 antibody and/or pharmaceutical composition.Type: ApplicationFiled: May 10, 2023Publication date: October 26, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Keisuke FUKUCHI, Kayoko NANAI, Masato AMANO, Kozo YONEDA, Yusuke TOTOKI, Shoji YAMAMOTO
-
Patent number: 11795236Abstract: As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(?O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(?O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting positionType: GrantFiled: September 13, 2018Date of Patent: October 24, 2023Assignee: DAIICHI SANKYO COMPANY, LIMITEDInventors: Hiroyuki Naito, Yusuke Ogitani, Takeshi Masuda, Takashi Nakada, Masao Yoshida, Shinji Ashida, Koji Morita, Hideki Miyazaki, Yuji Kasuya, Ichiro Hayakawa, Yuki Abe
-
Publication number: 20230330248Abstract: [Problem] It is desired to develop an antibody-drug conjugate capable of being systemically administered and delivering a STING agonist specifically to a target cells or organ (for example, a tumor lesion), and a therapeutic agent and/or therapeutic method using the antibody-drug conjugate for diseases related to STING agonist activity, for example, diseases (for example, cancers) to which immunostimulation therapy can be applied. [Solution] The present invention provides a novel antibody-CDN derivative conjugate which can be systemically administered and exhibits an antitumor effect against an antigen-expressing tumor.Type: ApplicationFiled: March 5, 2021Publication date: October 19, 2023Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Masayuki ISHIZAKI, Osamu SUZUKI, Mariko KYUTOKU, Hiroshi YUKIURA, Kyoko HARA, Masataka CHIHARA, Takafumi OTSUKA, Teiji WADA
-
Publication number: 20230331700Abstract: An object of the present invention is to provide a compound having an anti-inflammatory activity or a pharmacologically acceptable salt thereof. The solution of the present invention is a compound of general formula (1) or a pharmacologically acceptable salt thereof. wherein the symbols in the formula are defined below: A: e.g., Benzene, E: e.g., —CH2—, G: e.g., a 5-membered aromatic heterocyclic ring, X: e.g., cyclohexane, J: e.g., a 5-membered aromatic heterocyclic ring, Y: e.g., a phenyl group, R1, R2, R3: e.g., a halogen atom, R4: e.g., a C1-C6 alkyl group, R5: e.g., a hydrogen atom, R6a, R6b, R6c, R6d: e.g., a hydrogen atom, R7: e.g., a hydrogen atom, R8: e.g., a hydrogen atom, n1, n2, n3: e.g., 1.Type: ApplicationFiled: November 21, 2022Publication date: October 19, 2023Applicant: Daiichi Sankyo Company, LimitedInventors: Toru Taniguchi, Osamu Iwamoto, Keiji Saito, Katsuyoshi Nakajima, Yasuyuki Ogawa, Nobuya Kurikawa, Seiko Nagata, Kaori Ito, Eriko Kioi